Tg Therapeutics (TGTX) Non-Current Assets (2010 - 2026)

Tg Therapeutics' Non-Current Assets history runs 17 years deep, the most recent figure standing at $441.9 million for Q1 2026.

• In Q1 2026, Non-Current Assets rose 3528.11% year-over-year to $441.9 million; the TTM figure through Mar 2026 stood at $1.3 billion (up 2716.69% YoY), while the FY2025 annual figure was $432.5 million, up 3716.87% from the prior year.
• Non-Current Assets was $441.9 million for Q1 2026 at Tg Therapeutics, up from $432.5 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $441.9 million in Q1 2026 to a low of $11.3 million in Q4 2024.
• Historically, Non-Current Assets has averaged $95.1 million across 5 years, with a median of $12.7 million in 2024.
• The sharpest annual moves came in 2023 and 2025: Non-Current Assets tumbled 79.32% in 2023, then surged 3716.87% in 2025.
• A 5-year view of Non-Current Assets shows it stood at $25.3 million in 2022, then slumped by 53.97% to $11.6 million in 2023, then slipped by 2.69% to $11.3 million in 2024, then soared by 3716.87% to $432.5 million in 2025, then advanced by 2.17% to $441.9 million in 2026.
• The last three Non-Current Assets figures came in at $441.9 million (Q1 2026), $432.5 million (Q4 2025), and $425.3 million (Q3 2025), per Business Quant data.